Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

    3 hours ago

    Jefferies raised its target price on Divi’s Laboratories to Rs 12,550, citing upcoming CDMO commercialisation, peptide opportunities, and stronger growth prospects.
    Click here to Read More
    Previous Article
    Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why
    Next Article
    Thermax Q2 Review Review: JPMorgan Upgrades To Overweight, Kotak, UBS Maintain Buy | Check Target Prices

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment